New drug combination for advanced prostate cancer patients

NICE (National institute for health and care excellence) has approved a new drug combination for 1st line treatment of hormone refractory cancer.

The combination is made up of two drugs.

(A) talazoparib, (B) enzalutamide.

Enzalutamide is already being used for treatment of prostate cancer. Using Enzalutamide along with new drug talazoparib was found to significantly improves survival outcomes in a large clinic trial.

In USA, combination of talazoparib plus enzalutamide  has been approved only for patients with certain genetic mutations. The FDA has not approved the combination for patients without specific mutations .

In contrast, NICE in UK has approved combination of “talazoparib plus enzalutamide” for all patients irrespective of mutations. People with HRR gene mutations seem to derive the most benefit from the combination of talazoparib plus enzalutamide.

References

  1. NICE. Thousands could benefit from new take-at-home treatment for advanced prostate cancer . 23 January 2026
  2. NICE Guidance. Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004].
  3. Urology times. News|Articles|June 17, 2025. FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC
    Author(s)Hannah Clarke
  4. Lancet: Volume 406, Issue 10502P447-460. August 02, 2025.
    Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.

Disclaimer: Please note – This blog is NOT medical advice. This blog is NOT a expert medical opinion on various topics. This blog is purely for information research only and do check the sources where cited. Please DO consult your own doctor to discuss concerns and options, which are relevant and specific to you. The views expressed in this blog are NOT, in any way whatsoever, intended to be a substitute for professional advice. The blog is NOT previewed, commissioned or otherwise endorsed, in any way, by any organisation that the author is associated with. The views expressed in this blog likely represents some of the author’s personal views held at the time of drafting the blog and MAY CHANGE overtime, particularly when new evidence comes to light.